HomeCompareKWGPF vs ABBV

KWGPF vs ABBV: Dividend Comparison 2026

KWGPF yields 10526.32% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KWGPF wins by $25725.31M in total portfolio value
10 years
KWGPF
KWGPF
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25725.41M
Annual income
$1,277,554,475.51
Full KWGPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KWGPF vs ABBV

📍 KWGPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKWGPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KWGPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KWGPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KWGPF
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$1,085,921,304.18/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, KWGPF beats the other by $1,085,900,248.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KWGPF + ABBV for your $10,000?

KWGPF: 50%ABBV: 50%
100% ABBV50/50100% KWGPF
Portfolio after 10yr
$12862.76M
Annual income
$638,789,623.64/yr
Blended yield
4.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KWGPF
No analyst data
Altman Z
-0.3
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KWGPF buys
0
ABBV buys
0
No recent congressional trades found for KWGPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKWGPFABBV
Forward yield10526.32%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$25725.41M$102.3K
Annual income after 10y$1,277,554,475.51$24,771.77
Total dividends collected$20770.57M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KWGPF vs ABBV ($10,000, DRIP)

YearKWGPF PortfolioKWGPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$537,016$526,315.79$11,550$430.00+$525.5KKWGPF
2$13,782,078$13,207,471.46$13,472$627.96+$13.77MKWGPF
3$173,138,942$158,392,118.28$15,906$926.08+$173.12MKWGPF
4$1,115,080,713$929,822,045.11$19,071$1,382.55+$1115.06MKWGPF
5$3,991,457,867$2,798,321,503.70$23,302$2,095.81+$3991.43MKWGPF
6$8,951,541,324$4,680,681,406.28$29,150$3,237.93+$8951.51MKWGPF
7$14,483,404,111$4,905,254,894.95$37,536$5,121.41+$14483.37MKWGPF
8$19,205,933,259$3,708,690,860.18$50,079$8,338.38+$19205.88MKWGPF
9$22,848,462,901$2,298,114,313.04$69,753$14,065.80+$22848.39MKWGPF
10$25,725,409,779$1,277,554,475.51$102,337$24,771.77+$25725.31MKWGPF

KWGPF vs ABBV: Complete Analysis 2026

KWGPFStock

KWG Group Holdings Limited, together with its subsidiaries, engages in the property investment and development and hotel operations business. Its property portfolio includes mid- to high-end residential properties, serviced apartments, villas, offices, hotels, and shopping malls. The company was formerly known as KWG Property Holding Limited and changed its name to KWG Group Holdings Limited in August 2018. KWG Group Holdings Limited was founded in 1995 and is headquartered in Guangzhou, the People's Republic of China.

Full KWGPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KWGPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KWGPF vs SCHDKWGPF vs JEPIKWGPF vs OKWGPF vs KOKWGPF vs MAINKWGPF vs JNJKWGPF vs MRKKWGPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.